Quick Answer
Liminatus Pharma, Inc. reported Net Income of -$10.21 million for fiscal year 2025.
Liminatus Pharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$10.21M | -187.8% |
| 2024 | -$3.55M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.82M | -203.2% | -1709.5% |
| June 30, 2025 | $113.3K | +111.8% | +134.6% |
| March 31, 2025 | -$327.5K | +81.3% | +45.5% |
| September 30, 2024 | -$601.4K | — | +37.4% |
| June 30, 2024 | -$961.2K | — | +45.2% |
| March 31, 2024 | -$1.75M | — | — |
- Liminatus Pharma, Inc. showed a decrease of -187.8% in Net Income compared to the prior fiscal year.
- Over the 2024–2025 period, Liminatus Pharma, Inc.’s net income has declined by 187.8% (from -$3.55 million to -$10.21 million).
- The most recent figure is from Liminatus Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: